Obstructive airway diseases including asthma, chronic obstructive pulmonary disease and cystic fibrosis present with dyspnea and variety of other symptoms. Physiologically, they are characterized by maximal expiratory flow limitation and pathologically, by inflammation of the airways and the lung parenchyma. Inflammation plays a major role in the gradual worsening of the lung function resulting in worsening symptoms. For many years, scientists focused their efforts in identifying various pathways involved in the chronic inflammation present in these diseases. Further, studies are underway to identify various molecular targets in these pathways for the purpose of developing novel therapeutic agents. Natural agents have been used for thousands of years in various cultures for the treatment of several medical conditions and have mostly proven to be safe. Recent in vivo and in vitro studies show potential anti-inflammatory role for some of the existing natural agents. This review provides an overview of the literature related to the anti-inflammatory effects of some of the natural agents which have potential value in the treatment of inflammatory lung diseases.
Introduction
The chronic inflammatory response of the respiratory tract depends to some degree on the pathophysiology of the specific disease [Reed and Kita, 2004; Bunnett, 2006; Rahman and tions, causes desquamation, produces cytokines, chemokines, and growth factors, hyperemia, extravasation of plasma proteins, granulocyte infiltration, and alterations in epithelial permeability. Agonists of PARs, especially PAR2, induce inflammation in many tissues and these effects are mediated in part by the release of neuropeptides substance P and calcitonin gene-related peptide from sensory nerve fibers in peripheral tissues. The variety of PAR, PAR-2, one of the four PARs that have been characterized, is increased on the airway epithelium of patients with asthma. Two endogenous enzymes trypsin, released by injured epithelial cells, and tryptase of mast cells are potent activators of PAR-2. In addition mast cell chymase activates PAR-1. The exogenous proteases from mites and molds may operate through similar receptors. The synergistic action of two type of proteases amplify IgE production to allergens, degranulate eosinophils, and can generate inflammation, even in the absence of IgE. Similar proteases have been recently implicated in the pathogenesis of chronic hyperplastic rhinitis and polyps and intrinsic asthma. In contrast to asthma, inflammation in chronic obstructive pulmonary disease (COPD) leads to progressive destruction of lung parenchyma, airway remodeling and pulmonary emphysema [Rahman and Adcock, 2006; Tuder et al. 2006; Muro, 2007; Hogg et al. 2004; SAETTA, 1999] . Pathologically, COPD is characterized by influx of inflammatory cells into the airway, oxidative stress, increased proteolytic activity, and apoptosis. These mechanisms cause chronic airway inflammation leading to destruction and remodeling of lung tissue and result in chronic airway obstruction and appearance of emphysema [Fira-Mladinescu et al. 2007; Demedts et al. 2006 ]. The recruitment of inflammatory cells into the lung includes macrophages, neutrophiles, and T-lymphocytes [Barnes and Hansel, 2004; Culpitt et al. 2003] (Figure 2) . In COPD, the reactive oxygen species (e.g. induced by cigarette smoke) may enhance inflammation through the activation of stress kinases (c-Jun activated kinase, extracellular signalregulated kinase, p38) and transcription factors, i.e. nuclear factor (NF)-kappaB and activator protein-1 with increased pro-inflammatory mediators. These processes increase histone modifications, e.g. acetylation and inhibition of histone deacetylation leading to inflammatory gene expression. Transcription of inflammatory genes is facilitated by acetylation of core histones, which opens the chromatin structure, and initiates transcription factors and RNA polymerase to bind to DNA. The reduced expression of histone deacetylases (HDACs), particularly HDAC-2 is thought to be a key mechanism in COPD airway inflammation [Barnes, Adcock, and Ito, 2005] . In addition, the animal studies suggest that activated caspases, deficiency of vascular endothelial growth factor (VEGF), oxidants, ceramide, CD8+ T-lymphocytes, elastases, and interferon-gamma may be responsible for the induction of apoptosis of alveolar wall cells. The defective clearance of apoptotic cells in the lungs of patients with emphysema may promote inflammation.
In cystic fibrosis, lack of functional transmembrane conductance regulator (CFTR) in the apical membranes of airway's epithelial cells reduces or prevents mucociliary transport and clearance of bacteria and cAMP-dependent anion transport [Machen, 2006] . Loss of Cl-, HCO3-, and glutathione secretion may lead to reduced volume and increased acidification and oxidation of the airway surface liquid. These changes and the bacteria, i.e. Pseudomonas aeruginosa, accumulated in the mucus facilitate release and accumulation of bacterial flagellin which activates epithelial Toll-like receptor 5, subsequent NF-kappaB and release of proinflammatory cytokines that attract neutrophils to the infected region. This response to a cystic fibrosis challenge is termed hyperinflammatory due to massive neutrophils accumulation that directly damages the lung tissue.
Targeting airway and lung inflammation is an important treatment modality in the clinical management of most inflammatory airway diseases such asthma, COPD and cystic fibrosis. However, the options available for such antiinflammatory therapy are limited to only a few agents such as inhaled corticosteroids. Therefore, there is a great need to identify novel targets to combat airway inflammation. The use of natural agents may have a potential benefit and is reviewed below.
Effects of diet
Diet and nutrition may affect the onset and course of chronic inflammatory airway diseases. Serum lycopene and vitamin A concentrations were found to be significantly lower in asthmatics than in healthy control subjects [Riccioni et al. 2007; Romieu and Trenga, 2001] . In contrast, serum concentration of vitamin E and betacarotene were not significantly different in the two groups. Data also suggest that consumption of fish and foods high in omega-3 fatty acids may have a protective effect against allergic lung disease. Among children, consumption of fresh fruit, particularly fruit high in vitamin C, has been related to a lower prevalence of asthma symptoms and improved lung functions [Romieu and Trenga, 2001] . Antioxidant vitamins could also play an important role in gene-environment interactions in complex lung diseases such as childhood asthma. Dietary supplementation or adequate intake of lycopene, vitamin A, genistein and vitamin C rich foods may be beneficial in asthmatic subjects.
Many foods may affect development of COPD [Romieu and Trenga, 2001] . Food rich in vitamin C and E may play an especially important role in the prevention and treatment of COPD. Some population subgroups with higher levels of oxidative stress, such as cigarette smokers, may be more likely to benefit from dietary supplementation, since some studies suggested that antioxidant intake may have an impact in such patients. Studies of lung function decrement and COPD in adults suggest that daily intake of vitamin C at levels exceeding the current Recommended Dietary Allowance (60 mg/day among nonsmokers and 100 mg/day among smokers) may have a protective effect [Romieu and Trenga, 2001] . In one study, an increase of 40 mg/day in vitamin C intake led to an approximate 20 ml increase in FEV1 [Romieu and Trenga, 2001 ].
An epidemiological study studying the impact of dietary selenium and carotenoids on major causes of mortality and morbidity(including COPD) in elderly women showed a lower risk of mortality in subjects with higher serum selenium and serum total carotenoids levels [Ray et al. 2006 ].
Two dietary patterns were identified and studied in men and women populations in relation to COPD: a prudent pattern, i.e. high intake of fruits, vegetables, fish and whole grain products, and a Western pattern, i.e. high intake of refined grains, cured and red meats, desserts and French fries. Between 1986 and 1998, 111 self-reported cases of newly diagnosed COPD were identified among 42 917 men [Varraso et al. 2007b ].
In a similar study data were collected from a large prospective cohort of US women (Nurses' Health Study). Between 1984 and 2000, 754 self-reported confirmed cases of newly diagnosed COPD were identified among 72 043 women [Varraso et al. 2007a ]. The prudent pattern was inversely associated with the risk of newly diagnosed COPD and the Western pattern was positively associated with the risk of newly diagnosed COPD. In men and women, a diet rich in fruits, vegetables and fish may reduce the risk of COPD whereas a diet rich in refined grains, cured and red meats, desserts and French fries may increase the risk of COPD.
Vitamin A and E deficiency is common finding in cystic fibrosis [Bines et al. 2005] . However, analysis of newly diagnosed cystic fibrosis cases of infants with the disease showed no association between serum vitamin levels at diagnosis and airway inflammatory indices at either diagnosis or 12 months later. Therefore there is no evidence to implicate vitamin A or E deficiency in the development of lung disease or airway inflammation during infancy. Several studies have demonstrated essential fatty acid deficiency in plasma and tissue lipids of cystic fibrosis patients [Wood, Fitzgerald, and Garg, 2003 ]. The causes of this deficiency are believed due to reduced EFA intake, increased metabolism of arachidonic acid, malabsorption of fat, altered desaturase/lipase activity and defective cystic fibrosis transmembrane conductance regulator (CFTR) altering utilization of EFA in epithelial cells.
There is also evidence that elevated oxidative damage to EFA and impaired antioxidant defense, in particular vitamin E, may contribute to the development of EFA deficiency in CF. Furthermore, antioxidant supplementation in CF may improve EFA status.
In summary, epidemiological studies indicate that higher levels of antioxidant nutrients are associated with better lung function and may play role in prevention and management of inflammatory airway disease [Hu and Cassano, 2000 ].
Natural agents with potential therapeutic anti-inflammatory effects
Resveratrol & Pterostilbene Resveratrol (trans-3,5,4 -trihyroxystilbene) is a polyphenoic phytoalexin produced by many plants for its antifungal property [Wenzel and Somoza, 2005; Olas and Wachowicz, 2005; Schouten et al. 2002; Donnelly et al. 2004] . Pterocarpus marsupium Roxb. Fam. Leguminoseae is a large tree that commonly grows in the central, western, and southern parts of India and in Sri Lanka. The bark and wood of this tree is source of pterostilbene (trans-3,5-dimethoxy-4 -hydroxystilbene), a dimethyl ether analogue of resveratrol ( Figure 3 ) [Pan et al. 2007 ].
Resveratrol is found in many fruits, nuts, flowers, seeds, and bark of many plants [Olas and Wachowicz, 2005] . Resveratrol is produced in plants with the help of the enzyme stilbene synthase for its antifungal activity [Wenzel and Somoza, 2005] . It is made in higher concentration in grapes in response to fungal invasion. Therefore grapes grown in cooler climate tend to have higher concentration of resveratrol due to higher rate of fungal infection Review in a cooler environment [Celotti et al. 1996 ].
Although resveratrol is present in many plants, such as raspberries, mulberries, plums, peanuts, berries of Vaccinium species, cranberries, some pines, and roots and stalks of giant knotweed and Japanese knotweed, resveratrol's most abundant natural sources are Vitis vinifera, labrusca, and muscadine grapes, which are used to make wine [Celotti et al. 1996; Wenzel and Somoza, 2005; Olas and Wachowicz, 2005] . The content of resveratrol in wine is depended on the length of time the grape skins are present during the fermentation process. Therefore, the concentration of resveratrol is significantly higher in red wine than in white wine and grape juice, because the skins are removed earlier during the white wine production and no fermentation process is used in making grape juice. A fluid ounce of red wine averages 160 micrograms of resveratrol, compared to peanuts, which averages 73 ug per ounce [Juan et al. 1999 ]. Since wine is the most notable dietary source, it is the object of much speculation and research.
Due to the "French Paradox" in which wine consumption was associated with reduced risk and lowered mortality from coronary heart disease [Donnelly et al. 2004; Birrell et al. 2005; Renaud and de Lorgeril, 1992; Renaud and Ruf, 1994; Renaud and Gueguen, 1998 ], resveratrol received wide attention recently. Resveratrol is found in abundant amount in wine ranging from 0.2 to as much as 40 mg/L depending on the type of grape it is made from [LeBlanc, 2006] . In grapes, resveratrol can be found in roots, stalks, vines, and seeds but its highest concentration is in the skin. In animal and human model, resveratrol has been shown to have many beneficial biological properties. Those properties include antioxidative [Olas and Wachowicz, 2005; Donnelly et al. 2004; Birrell et al. 2005; Rahman, Biswas, and Kirkham, 2006; Orallo 2006; Leiro et al. 2004; Fremont, 2000] , anti-inflammatory [Fremont, 2000; Rahman, Biswas, and Kirkham, 2006; Donnelly et al. 2004; Olas and Wachowicz, 2005] , anti-carcinogenic [Olas and Wachowicz, 2005; Donnelly et al. 2004; Fremont, 2000; Zunino and Storms, 2006] , chemo-preventive [Olas and Wachowicz, 2005; Shankar, Singh, and Srivastava, 2007] , and immunomodulatory activities [Sharma et al. 2007 ]. Most studies done thus far on resveratrol have been done on either animal model or in-vitro human model.
Antioxidant and anti-inflammatory properties are the two most studied biological activities of resveratrol. Most studies consistently show resveratrol decrease reactive oxygen species by increasing free-radical scavenger activities [Murcia and Martinez-Tome, 2001; Olas et al. 2001; Stojanovic, Sprinz, and Brede, 2001] , inhibits lipid peroxidation [Lu et al. 2002] in a concentration-dependent manner [Murcia and Martinez-Tome, 2001 ] and deoxyribose attack [Murcia and Martinez-Tome, 2001] . A recent study showed when resveratrol was administered intraperitoneally into rats, brain malondialdehyde level decreased in a dose-dependent fashion, whereas, brain superoxide dismutase, catalase, and peroxidase activities increased in a dosedependent relationship [Mokni et al. 2007 ].
There are several potential mechanisms contributing to resveratrol's anti-inflammatory properties. Resveratrol inhibits transcription factor NF-kB [Nam, 2006] , activator protein-1 (AP-1), and cAMP response element binding protein-dependent transcription [Manna, Mukhopadhyay, and Aggarwal, 2000 ]. Both NF-kB and AP-1 are transcription factors involved in the expression of many inflammatory genes inducible by oxidative stress [Donnelly et al. 2004] . In a study of alveolar macrophage in COPD, resveratrol blocked the release of both IL-8 and GM-CSF from alveolar macrophages in smokers and in patients with COPD both at basal state and at stimulated cytokine release state induced by IL-1B and cigarette smoke medium (CSM) [Culpitt et al. 2003 ]. In both human mammary epithelial cells and macrophages in rats and murine model, resveratrol reduced the level of cyclooxygenase (COX-2) transcription and iNOS (inducible nitric oxide synthase). Further, resveratrol may impair expression of IL-1 and TNF-a [Richard et al. 2005 ]. Another study done on the effects of resveratrol on human lung epithelial cells has demonstrated reduction of iNOS expression, COX-2 mRNA, and production of IL-8 and GM-CSF [Donnelly et al. 2004] . In this study, resveratrol was shown to selectively inhibits transcription factor NF-kB, AP-1, and CRE dependent pro-inflammatory gene expression [Donnelly et al. 2004] . When compared to glucocorticoids, resveratrol is although less potent but appear to be more effective in suppressing inflammatory activity. Both resveratrol and glucocorticoids exerts their antiinflammatory effects by different mechanisms. Furthermore, certain pro-inflammatory pathways are not affected by steroid but are inhibited by resveratrol (ex. iNOS) [Donnelly et al. 2004] . Although glucocorticoids are potent antiinflammatory agent, in most clinical studies, glucocorticoids have not been shown to reduce airway inflammation associated with COPD and it does not alter the course of COPD. More studies need be done to understand how resveratrol fits into inflammatory pathways, which will help in development of novel therapies using resveratrol for treatment of COPD and other chronic inflammatory airway diseases.
Resveratrol was evaluated in in vivo experimental model to determine its role in rodent model of LPS induced airway inflammation [Donnelly et al. 2004] . Resveratrol reduced lung tissue infiltration with neutrophils. This was associated with a reduction in pro-inflammatory cytokines and prostanoid levels. In this study the reduction of inflammatory reaction did not appear to be due to resveratrol's inhibition of NF-kB activation. Resveratrol may exert anti-inflammatory properties via a novel mechanism.
In the in vitro study with human epithelial cells, resveratrol and the related molecule quercetin inhibited IL-8 and granulocyte-macrophage colony-stimulating factor release from A549 cells [Shen et al. 2003 ]. Neither the estrogen receptor antagonist tamoxifen nor the glucocorticoid antagonist mifepristone altered the inhibitory effect of resveratrol. In comparison to dexamethasone, resveratrol and quercetin inhibited to the greater extent NF-κB, activator protein-1, and cAMP response element binding proteindependent transcription mechanism. Interestingly these compounds had no significant effect on acetylation or deacetylation of core histones. Resveratrol, but not estradiol or N-acetyl cysteine, inhibited cytokine-stimulated inducible nitric oxide synthase expression and nitrite production (IC50 = 3.6 +/− 2.9 microM) in human airway epithelial cells. Resveratrol also inhibited granulocyte-macrophage colony-stimulating factor release (IC50 = 0.44 +/− 0.17 microM), IL-8 release (IC50 = 4.7 +/− 3.3 microM), and cyclooxygenase-2 expression in these cells. Resveratrol and quercetin have distinct antiinflammatory mechanism from other botanicals with NSAID properties.
Modulation of interleukin-8 (IL-8) production in human monocytic cells by resveratrol and its mechanism at the gene transcription level was subject of the in vitro study [Cho et al. 2002] . The U937 cells were stimulated with phorbol 12-myristate 13-acetate (PMA) for 24h to induce the IL-8 secretion. The RNA level of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and IL-8 were detected by RT-PCR using specific primers. DNA binding activities of NF-kB and AP-1 were examined by electrophoretic mobility shift assay (EMSA). Dexamethasone (10microM) and resveratrol (10, 1, 0.1 microM) inhibited PMA-induced IL-8 production and mRNA accumulation. The AP-1 was inhibited by dexamethasone and resveratrol, but resveratrol has little effect on PMA-induced NF-kB activation. Resveratrol could inhibit PMA-induced IL-8 production in U937 cells at protein and mRNA levels. The suppression of IL-8 gene transcription by resveratrol was due to inhibition of AP-1 activation.
NF-kB controls the expression of genes encoding the pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-6, TNF-a), chemokines like IL-8, adhesion molecules (ICAM, VCAM, and E-selectin), inducible enzymes (COX-2 and iNOS), growth factors, and immune receptors, all of which play an important role in inflammatory process Nam, 2006; Richard et al. 2005; Martin et al. 2006; Csiszar et al. 2006; Wung et al. 2005; Holmes-McNary and Baldwin, Jr. 2000 ].
Inhibition of NF-kB by resveratrol is thought to be mediated by blocking IkB kinase [Holmes-McNary and Baldwin, Jr. 2000 ]. Resveratrol also inhibits AP-1, which is another transcription factor important in the regulation of many other genes that are responsible for inflammatory cytokines production [Babcock et al. 2003 ]. Thus, resveratrol blocks 2 major proinflammatory pathways at transcription stage that are responsible for many inflammatory genes which may be induced by oxidative stress [Karin, 1995] . It is still not clear whether the anti-inflammatory properties of resveratrol are due only to the inhibition of transcription factor NF-kB and AP-1. Resveratrol may also impair production of certain pro-inflammatory protein at local level by a different pathway. Understanding details of these mechanisms of action by resveratrol may lead to a development and application of novel anti-inflammatory therapies for many chronic inflammatory diseases.
Review
Resveratrol has been studied extensively in last few years for its potential anti-carcinogenic, chemoprevention, and immunomodulatory effects. In both animal and in vitro human models, resveratrol inhibited tumor initiation, promotion, and progression. These effects are most likely due to resveratrol's inhibition of metabolic activation of carcinogens as well as it's properties of antioxidant, anti-inflammatory, anti-proliferative, and pro-apoptosis activities [Bianchini and Vainio, 2003] . In a mouse lung cancer model, resveratrol induced caspasemediated cancer cell apoptosis and inhibited angiogenesis via suppressed basic fibroblast growth factor (bFGF) receptor binding [Lee et al. 2006 ]. In human lung cancer cell model, resveratrol exerts both anti-proliferative and apoptosis effects. This anti-proliferative effect causes cell growth arrest at G1 and G1/S phases of cell cycle which is mediated by both inhibition of the phosphrylation of the retinoblastoma protein (pRB) and induction of cyclindependent kinase (Cdk) inhibitor p21WAF1/CIP and p27/KIP1 [Shankar, Singh, and Srivastava, 2007] . Its apoptosis effect in human can be mediated through either caspase-dependent apoptosis [Kim et al. 2003] or up-regulating expression of Bax, Bak, PUMA, Noxa, Bim, p53, TRAIL, TRAIL-R1/DR4 and TRAIL-R2/DR5, and simultaneously down-regulating the expression of Bcl-2, Bcl-DL, and Mcl-1 [Shankar, Singh, and Srivastava, 2007] . Furthermore, resveratrol's anti-inflammatory effect through inhibition of transcription factor NF-kB reduces the pro-inflammatory proteins and pushes transformed cancer cells into pro-apoptotic state and potentiates the apoptotic effects of cytokines, chemotherapeutic agents, and gamma-radiation [Shankar, Singh, and Srivastava, 2007] .
The anti-inflammatory properties of resveratrol, especially it's pleiotrophic mode of action and potential targets at relative upstream of pro-inflammatory pathway involving multiple transcription factors (e.g., NF-kB and AP-1), makes it a very attractive agent for development and application of novel therapies for many chronic inflammatory lung disease (e.g., COPD, asthma, ILD).
Curcumin and crcuminoids
Curcumin and curcuminoids are substances derived from the plant, Curcuma longa. As a spice, turmeric is widely used as a medicinal agent in many parts of the world, especially the Indian subcontinent. Curcumin exhibits antioxidant, anti-inflammatory, antiviral, antibacterial and anticancer activities. Curcumin may be an ideal agent for many inflammatory airway diseases because it has potent antiinflammatory effects through varied mechanisms. These include enzyme modulation resulting in the inhibition of the cyclooxygenase and lipooxygenase pathways, inhibition of iNOS induction, inhibition and modulation of inflammatory cells, production of cytokines and inhibition of transcription.
An increase in prostaglandin synthesis from arachadonic acid is a key feature of inflammation. This is mediated by a key enzyme called cyclooxygenase, which has two isoforms, COX-1 and COX-2. Curcumin inhibits the expression of COX-2 at the transcriptional level [Hong et al. 2004; Menon and Sudheer, 2007] . Another important enzyme that mediates inflammation is inducible nitric oxide synthase (iNOS). iNOS mediates the production of nitric oxide(NO) which is a strong proinflammatory agent. Increased expression of iNOS has been observed in many inflammatory disorders, including asthma. Curcumin has been found to inhibit the expression of iNOS and thus the production of NO. Brouet et al. showed that curcumin inhibits induction of iNOS in activated macrophages while Chan et al. showed that curcumin inhibits the expression of nitric oxide synthase gene expression [Menon and Sudheer, 2007; Surh et al. 2001; Brouet and Ohshima, 1995; Chan et al. 1998; Lin, 2007] .
Tumor necrosis factor (TNF) is also involved in the pro-inflammatory pathway of many airway diseases. These effects are due to the activation of nuclear factor kB (NF-kB). NF-kB is a transcription factor which when activated translocates to the nucleus and induces the transcription of a large variety of target genes that encode cytokine production. Agents that suppress TNF and NF-kB can therefore play a key role in suppression of inflammation. Curcumin inhibits the activation of NF-kB and prevents its translocation to the nucleus. Curcumin inhibits the expression of TNF mRNA as well as TNF protein leading to a reduced TNF and NF-kB level and decrease in inflammation [Lin, 2007; Menon and Sudheer, 2007] .
Furthermore, curcumin may exert direct antiinflammatory effects through the modulation of cells involved in inflammation. Neutrophils accumulation is the primary response in local inflammation which is followed by activation and infiltration of more neutrophils to the area of inflammation. Therefore, modulation of neutrophils activity can result in major antiinflammatory effects. Although, curcumin exerts a direct cytotoxic effect on neutrophils, its major anti-inflammatory effect on neutrophils is through IL-8. IL-8 is a chemotactic cytokine that activates and elicits migration of leukocytes. Takahashi et al. showed that curcumin significantly inhibited neutrophils migration in a dosedependent manner [Takahashi et al. 2007 ]. This inhibition was not due to curcumin-induced cytotoxicity but rather due to an anti-chemotaxis effect. Curcumin inhibits the production of IL-8 by monocytes, macrophages and other lymphatic cells. It also directly changes the IL-8 receptor trafficking pathway in cytosol.
In addition, curcumin affects the functioning of lymphocytes and macrophages. Sharma et al. showed that curcumin can inhibit both cell-mediated immunity and humoral immunity [Sharma et al. 2007 ]. The proliferation of Th1 lymphocytes that mediate cell-mediated immunity through the secretion of IFN-γ and IL-4 is suppressed by curcumin. Humoral immunity is mediated by Th2 cells secretion of IL-4 and B lymphocytes production of IgG. Curcumin has been found to decrease the proliferation of Th2 cells and the secretion of IgG1 and IgG2a. Curcumin is also thought to act on macrophages leading to an increase in the production of the anti-inflammatory cytokine, IL-10.
Some studies of the effects of curcumin on lung inflammation provided promising results. Kurup et al. showed a down-regulation of allergic inflammatory response in mice challenged intranasally with latex allergens with curcumin administration [Kurup et al. 2007 ]. Treatment with curcumin in this mouse model, which has all the distinguishing features of IgE-mediated allergy, showed a complete disappearance of eosinophils, reduced total IgE levels and a consistent reduction in the inflammatory response. This shows the potential of curcumin in the management of allergic asthma.
In chronic obstructive pulmonary disease (COPD), curcumin may have many potential therapeutic effects. Reactive oxidative stress is thought to play a role in the pathogenesis of COPD [Rahman and Adcock, 2006 ]. Smoking increases the oxidant burden in the lungs due to increased release of reactive oxidant species from macrophages and neutrophils. Smokers and patients with COPD have increased numbers of neutrophils in the airways especially during exacerbations. In addition, these neutrophils contain more myeloperoxidase and release more oxidants. Alveolar macrophages in the airways of smokers are more activated and release more free oxygen radicals than those in nonsmokers. Curcumin has multiple properties to protect against cigarette smoke-mediated oxidative stress. It acts as a free oxygen radical scavenger and increases the levels of the antioxidant glutathione by induction of glutamate cysteine ligase. This anti-oxidant property of curcumin in addition to the anti-inflammatory properties on inflammatory cells and mediators of inflammation make curcumin an attractive potential agent in the management of COPD. However, human studies on the effects of curcumin on inflammatory airway disease are needed.
Adathoda vasica Nees
Adhatoda vasica Nees. Fam. Acanthaceae is an evergreen plant indigenous to India and has been used by Ayurveda physicians for the management of respiratory disorders. A popular Sanskrit verse describes A. vasica in these words "When vasa is around and there is still a hope of life, why should a patient with tuberculosis, asthma or a bleeding diathesis be in despair and suffer?" The leaves of A. vasica contain essential oils as well as the quinazoline alkaloids vasicine, vasicinone, deoxyvasicine and maiontone [Claeson et al. 2000; CHEMEXIL, 1992] . Vasicine was shown to possess bronchodilatory effect and respiratory stimulant activities, whereas vasicinone, the auto-oxidation product of vasicine, showed bronchodilatory effect [CAMBRIDGE, JANSEN, and JARMAN, 1962; Gupta and et al. 1977] . Vasicinone was found to be more potent than vasicine with antiasthmatic activity comparable with disodium chromglycate. Vasicine and vasicinone mixed in 1:1 ratio showed in pre-clinical studies more bronchodilatory activity and antagonism against histamine-induced bronchoconstriction as compared with vasicine alone or theophylline [Gupta and et al. 1977] . A semisynthetic derivatives of vasicine, bromhexine (Bisolvon) and ambroxol have been developed as bronchial mucolytic, antiinflammatory and antioxidant compounds for use Review in chronic pulmonary disease [Gupta and et al. 1977; Grange and Snell, 1996; Stetinova, Herout, and Kvetina, 2004] . Another structural analog with anti-allergic properties was derived from vasicinone [Paliwa et al. 2000 ].
Bromhexine combined with tetracycline was compared with placebo in a 3 week double-blind crossover trial in 41 out-patients with chronic bronchitis and irreversible airways obstruction [Lal and Bhalla, 1975] . Results from the 36 patients who participated in this trial showed a statistically significant mucolytic effect and a significant improvement in overall clinical state as judged by the physician in a group receiving active treatment vs. placebo.
In another clinical study patients on bromhexine regimen improved significantly in the peak expiratory flow rate, ascultatory findings and sputum volume [Armstrong, 1976] . The results and review of the literature indicates that bromhexine is effective therapy for most patients with chronic bronchitis associated with thick, tenacious sputum.
In another double blind randomized study, 30 patients suffering from chronic obstructive bronchitis received bromhexine or ambroxol daily over a period of 4 weeks [Wiessmann and Niemeyer, 1978] . Bromhexine was not associated with a change in lung function parameters. However, ambroxol resulted in 25% reduction of the average bronchial flow resistance and improved forced expiratory volume on the average by 14% [Wiessmann and Niemeyer, 1978] . The patients reported that both compounds facilitated expectoration.
In a multicenter placebo controlled, randomized study, 237 out-patients with chronic obstructive lung disease (COLD) were selected to either receive placebo or bromhexine 30 mg bid [Valenti and Marenco, 1989] . Sputum volume and quality, facility of expectoration, cough, dyspnea, auscultatory thoracic symptoms, forced expiratory volume, peak expiratory flow rate and residual volume were evaluated. Bromhexine group showed a statistically significant therapeutic effect compared to the placebo.
Ambroxol and N-acetyl cysteine (NAC) have been proposed as therapeutic agents in the treatment of chronic pulmonary disorders [Aihara et al. 2000 ]. The effects of these two compounds on secretions of IL-12 and IL-10 from human alveolar macrophages obtained by bronchial lavage from 7 healthy nonsmokers have been investigated. IL-12 plays an important role in host resistance to infection and the development of Th-1 cells. On the other hand, IL-10 is involved in anti-inflammatory and immunoregulatory mechanisms. Cells were first incubated with either NAC or ambroxol and then cultured in the presence of lipopolysaccharide (LPS). Both NAC and ambroxol enhanced LPS-induced secretion of IL-12. NAC but not ambroxol enhanced LPS-induced IL-10 secretion while the ratio of IL-12/IL-10 secretion was increased by ambroxol but not NAC. These results suggest that NAC enhances anti-inflammatory response while ambroxol appears to strengthen innate immune response and cell-mediated immunity, and facilitate the development of Th-1 cells.
The effects of ambroxol and N-acetylcystein (NAC) on the release of histamine, leukotrienes, cytokines and superoxide anions from a variety of cells involved in the pathogenesis of allergic reaction and inflammation [Gibbs et al. 1999] . Ambroxol or NAC were incubated with mast cells, basophils, monocytes and granulocytes prior to stimulation the cells with mitogens. Ambroxol inhibited histamine release by more than 50% from human mast cells (1000 microM ambroxol) and mast cells (100 microM ambroxol) stimulated by Con A and compound 48/80, respectively. Ambroxol (100 microM) inhibited antibody IgE, induced release of histamine, LTC4, IL-4 and IL-13 from basophils, reduced histamine and LTB4 release induced by C5a or zymosan in monocytes. The compound also reduced LTB4 and superoxide anion production in granulocytes stimulated by zymosan. In all cell types studied, ambroxol was more effective after a 5-15 min preincubation of the drug with the cells before stimulation. In contrast, NAC produced no clear effects on any of the different cell types studied. Ambroxol can inhibit release of mediators of allergic reaction from mast cells and leukocytes which may explain its role in treatment of allergic and inflammatory respiratory diseases.
Ambroxol was evaluated in inflammatory responses in a murine model of lipopolysaccharideinduced lung injury [Su et al. 2004] . Mice were challenged with intratracheally instilled with lipopolysaccharide (LPS) and then received an intraperitoneal injection of either normal saline, ambroxol (30 or 90 mg/kg per day) or dexamethasone (2.5 or 5 mg/kg per day) for 7 days. Mice with LPS-induced lung injury on ambroxol gained weight compared to the control and dexamethasone-treated groups. Ambroxol and dexamethasone significantly reduced the lung hemorrhage, edema, exudation, neutrophil infiltration and total lung injury histology score. Compared to the control group, TNF-alpha, IL-6 and TGF-beta1 and total protein levels in the bronchoalveolar lavage in both ambroxol-and dexamethasone-treated groups were significantly reduced. Ambroxol inhibited proinflammatory cytokines, reduced lung inflammation and accelerated recovery from LPSinduced lung injury.
In addition to a mucolytic action, ambroxol has antioxidant and anti-inflammatory properties [Stetinova, Herout, and Kvetina, 2004] . The antioxidant effects of ambroxol were studied in in vitro methods (i.e. inhibition of hyaluronic acid degradation induced by hydroxy radicals and lipid peroxidation assay in rat liver mitochondria and gastric mucosa, induced by tert-butyl hydroperoxide) and the in vivo rat model of gastric corpus and antral lesions, induced by indomethacin. The inhibition of the degradation of hyaluronic acid was measured as a change of its viscosity; ambroxol (1,000 microl/l) reduced the degradation by 93%. Ambroxol (10 mmol/l) inhibited lipid peroxidation by 96% in the rat liver mitochondria, and by 74% in the gastric mucosa. Ambroxol was administered p.o. at a dose of 10-50 mg/kg, 5-60 min prior to indomethacin administration. The highest inhibition of the gastric lesions was shown after the administration of ambroxol 50 mg/kg, 30 min before indomethacin administration.
The radiomodulatory influence of ethanolic extract of Adhatoda vasica Nees leaf extract against radiation-induced hematological alterations in peripheral blood of Swiss albino mice was studied at various post-irradiation intervals between 6 h to 30 days [Kumar et al. 2005] . Oral administration of A. vasica leaf extract (800 mg/kg body weight) prior to whole body irradiation (8.0 Gy) showed a significant protection in terms of survival percentage and hematological parameters. No control animal could survive beyond day 25. Conversely, animals pretreated with A. vasica leaf extract showed 81.25% survival till 30 days after exposure and a gradual recovery was noted in the hematological values.
A significant decrease in blood reduced glutathione (GSH) content and increase in lipid peroxidation level was observed in control animals. However, A. vasica leaf extract pretreated irradiated animals exhibited a significant increase in GSH content and decrease in lipid peroxides level. A significant increase in the serum alkaline phosphatase activity and decrease in acid phosphatase activity was observed in A. vasica leaf extract pretreated irradiated animals during the entire period of study.
Picrorhiza kurroa Royle ex Benth.
Picrorhiza kurroa Royle ex Benth. Fam. Scrophulariaceae is a perennial herb that grows in the Himalaya Mountains at altitudes of 9000-15000 feet above sea level. Picrorhiza kurroa is used in Ayurveda medicine to treat disorders of the liver and respiratory tract, reduce fevers, to treat dyspepsia, chronic diarrhea, and scorpion sting. The roots and rhizomes of the plant are predominantly used for therapeutic purpose. However, new anti-oxidant and anti-inflammatory principles (ethyl acetate extract) have been isolated from seeds of the plant (picrorhiza acid, picrorhizoside A-C and triterpenoid compounds; Cox2 and lipid peroxidation inhibitors) [Kutkin, 2001; Zhang et al. 2004; Zhang et al. 2005 ].
The active principle phenol glycoside androsin was isolated from the roots of the plant. Androsin (10 mg/kg body weight p.o. or 0.5 mg inhaled) inhibits allergen and platelet-activating factor (PAF) induced bronchial inflammation and obstruction in experimental model in vivo in guinea pigs [Dorsch et al. 1991] . Administered with DSCG, P. kurroa prevented release of histamine from the inflammatory cells, and total histamine content of the lung tissue in experimental animals was significantly less than that of untreated control [Mahajani and Kulkarni, 1977] . It is plausible that P. kurroa mechanism in bronchial asthma is via stabilizing activity on mast cells.
Another active principle isolated from roots of P. kurroa is apocynin (4 -hydroxy-3 -methoxyacetophenone or acetovanillone). Apocynin is a selective inhibitor of NADPH oxidase present in inflammatory cells such as eosinophils and neutrophils [Peters, Hiltermann, and Stolk, 2001; Stolk, Rossie, and Dijkman, 1994] . Its mechanism in lung inflammatory disease maybe due to prevention of NADPH mediated oxidation of the methionine residue in the active Review site of secretory leukocyte protease inhibitor (SLPI). By shielding SLPI from inactivation apocynin may prevent inflammatory lung disease. Administered in drinking water (20 and 200 micrograms/ml) apocynin improved significantly the lung protective effect of inhaled SLPI against LPS-induced emphysema [Stolk, Rossie, and Dijkman, 1994] .
Enhanced expression of tumor necrosis factor (TNF) plays a critical role in airway smooth muscle hyperresponsiveness observed in asthma. TNF increases intracellular and extracellular oxidants (NADPH oxidase) production in guinea pig airway smooth muscle cells. The oxidants phosphorylatate light chains of smooth muscles, increasing contractility and narrowing of the airway passages. This reaction is abolished by inhibitors of NADPH oxidase, e.g. apocynin whereas inhibitors of mitochondrial respiratory chain, nitric-oxide synthase, cyclooxygenase, and xanthine oxidase had no effect on TNF production [Thabut et al. 2002] .
The reactive oxygen species produced by phagocytic cells are considered to play an important role in inflammation. Apocynin selectively inhibits reactive oxygen species production by activated human neutrophils [Van den et al. 2001; . Phagocytes are able to generate reactive oxygen species through the NADPH oxidase system. Oxygen uptake by neutrophils incubated with 300 microM apocynin was completely inhibited at 7 min after addition of serum-treated zymosan (STZ) ].
The effect of apocynin in neutrophils relatively deficient of myeloperoxidase was significantly delayed when compared with normal cells ]. Inhibition of the STZinduced respiratory burst by apocynin was also observed in human eosinophils but not in human alveolar macrophages. Apocynin is an intracellular inhibitor of the assembly of NADPH oxidase in neutrophils and eosinophils and that apocynin requires conversion by peroxidases to exert its inhibitory effect. Importantly, the intracellular killing of bacteria (Staphylococcus aureus) was not affected by apocynin.
NADPH oxidase is a major enzymatic source of oxygen free radicals in stimulated endothelial cells [Johnson et al. 2002] . Blocking the assembly of a functional NADPH oxidase complex, apocynin inhibits the release of superoxide anion (O2 * -) by this enzyme. The important stage in blocking mechanism is the reaction of apocynin with reactive oxygen species (ROS) and peroxidase; apocynin is converted to a symmetrical dimer through the formation of a 5,5 carbon-carbon bond. Both reduced glutathione and L-cysteine inhibit this dimerization process. Superoxide production by an endothelial cell-free system incubated with apocynin was nearly completely inhibited after a lagtime for inhibition of approximately 2 min. However, O2 * -production was nearly completely inhibited, without a lagtime, by incubation with the dimeric form of apocynin. Inhibition of endothelial NADPH oxidase by apocynin caused a dose-dependent inhibition of endothelial cell proliferation. Therefore metabolite of apocynin (ortho-methoxy-substituted catechol) may be the active compound formed within challenged endothelial cells of the respiratory tract that prevents NADPH oxidase complex assembly and activation.
Tylophora asthmatica (L.) Wight and Arnott Tylophora asthmatica (indica) (L.) Wight and Arnot, Fam. Asclepiadeceae is a perennial climber indigenous to Southern and Eastern India. The leaves of this creeper have been employed in Ayurveda for the treatment of asthma, as an expectorant, emetic and antidysenteric agent. The powdered leaves, stem and root contain 0.2-0.3% of phenanthroindolizidine alkaloids, mainly tylophorine, tylophorinine and tylophorinidine [Ali and Bhutani, 1989 ].
The plant extracts were found to produce significant anti-inflammatory effects in preclinical studies. The inflammatory models tested included adjuvant arthritis, hind-paw edema, granuloma pouch and cotton pellet-induced edema [Gopalakrishnan et al. 1979] .
Crude extract of alkaloids from the leaves of Tylophora indica inhibited delayed hypersensitivity reaction (DHT) to sheep red blood cells (SRBC) in rodents . Lymphocytes taken from contact sensitized mice (dinitro-fluorobenzene), when treated with tylophora alkaloid in vitro and transferred into naive syngeneic hosts, could suppress the transfer of DTH response. However, the extract could not suppress primary humoral (IgM) immune response to SRBC in mice. These studies suggest that tylophora alkaloids suppress cellular but not humoral immune response when administered at any stage during the immune response.
In a follow-up in vitro study,investigations were carried to determine the cellular targets of tylophora alkaloids [Ganguly, Badheka, and Sainis, 2001] . Concanavalin A induced proliferation of rodent splenocytes was used as a model system. The alkaloids were found to inhibit proliferation of splenocytes at higher concentrations and enhance proliferation at the lower concentrations. Both cultured macrophages and T cells were found to be targets of tylophora alkaloids. The alkaloids suppressed IL-2 production in Concanavalin A stimulated splenocytes at higher concentrations and enhanced production at the lower concentrations. Interestingly, the production of IL-1 by activated macrophages was significantly increased at the higher concentrations of alkaloids. Therefore tylophora alkaloids have a concentration dependent biphasic effect on Concanavalin A induced mitogenesis. At lower concentrations alkaloids augment Concanavalin A induced lymphoproliferation by enhancing IL-2 production; at higher concentrations proliferation is inhibited via activated macrophages and increased production of IL-1.
The alcoholic, petroleum and aqueous extracts of the leaves were found in vivo to antagonize dexamethasone/hypophysectomy-induced suppression of pituitary on the activity of the adrenals [Udupa, Udupa, and Guruswamy, 1991] . The experiment indicates that the immunosuppressive and anti-inflammatory effects of the plant may in part be due to increased secretion of corticosteroids by the direct effect of Tylophora asthmatica components on the adrenal cortex. In clinical studies the mean value of 17-ketosteroid excretion in the urine after T. asthmatica (100 mg dried leaf powder bid for six days) administration was significantly increased in healthy controls and in patients with asthma [Gore, Rao, and Guruswamy, 1980] . This finding coincided with a significant decrease in eosinophil blood count in asthmatic subjects.
The molecular mechanisms for the antiinflammatory activity of phenanthroindolizidine alkaloids were examined in an in vitro system mimicking acute inflammation by studying the suppression of lipopolysaccharide (LPS)/ interferon-gamma (IFNgamma)-induced nitric oxide production in RAW264.7 cells [Yang et al. 2006 ]. Tylophorine exhibited potent suppression of nitric oxide production and did not show significant cytotoxicity to the LPS/IFNgammastimulated RAW264.7 cells, in contrast to the cytotoxic effects on cancer cells. Tylophorine was studied further to investigate the responsible mechanisms. It was found to inhibit the induced tumor necrosis factor-alpha, inducible nitric-oxide synthase (iNOS), and cyclooxygenase type 2 (COX2). It also inhibited the activation of murine iNOS and COX2 promoter activity. Tylophorine enhanced the phosphorylation of Akt and thus decreased the phosphorylation and expression levels of c-Jun protein, which led to inhibition of adaptor protein (AP1) activity. Tylophorine was able to block mitogen-activated protein/extracellular signal-regulated kinase kinase 1 activity and its downstream signaling activation of NF-kappaB and AP1. Thus, tylophorine exerts its antiinflammatory effects by inhibiting expression of the signaling pathways for proinflammatory factors.
F. Glabridin and gycyrrhetic acid
Glabridin and gycyrrhetic are compounds derived from the roots of licorice, Liqueritia glabra L. Glabridin possesses anti-inflammatory, antimicrobial, and cardiovascular protective activities. Glabridin inhibited intercellular adhesion molecule-1 (ICAM-1) expression in TNF-αstimulated human umbilical vein endothelial cells (HUVECs) [Kang et al. 2005] . Glabridin inhibited THP-1 cell adhesion to HUVECs stimulated by TNF-α and cell surface expression of ICAM-1 in TNF-α-stimulated HUVECs. The mRNA expression of adhesion molecules was also suppressed by glabridin. Further study demonstrated the inhibition of NF-κB DNA binding, inhibition of the chain reaction leading to translocation and activation of NF-κB. Glabridin inhibits both inducible and constitutive NF-κB. In addition, TNF-α-induced phosphorylation of Akt and extracellular signal-regulated kinase (ERK) was blocked by the treatment.
Beta-glycyrrhetinic acid (GA), a saponin isolated from licorice roots, displayed inhibitory action on TNF-α-induced IL-8 production in human colonic epithelial cells [Kang et al. 2005] . Interleukin (IL)-8 plays a central role in inflammatory responses, and its function requires activation of NF-κB. GA inhibited TNF-α-induced phosphorylation of p38 MAPK and ERK, IκB Review alpha degradation, and NF-κB activation. These results suggest that GA has inhibitory effects on TNF-α-induced IL-8 production in the intestinal epithelial cells through the inhibition of phosphorylation of MAPKs, following I kappa B alpha degradation and NF-κB activation.
Summary
Inflammation plays a major role in chronic airway diseases like asthma and COPD. Recent advances identified several inflammatory pathways that are implicated in airway and parenchymal inflammation. Scientists have been developing molecular targets for therapeutic purposes. Naturally occurring substances may exert some antiinflammatory effects by modulating some of the inflammatory pathways. These agents have been used in different cultures for thousands of years and have proven to be relatively safe. Preliminary in vitro and in vivo studies are promising. However, properly conducted clinical trials with these agents are not available. While further studies are conducted to better define the mechanism of action of these agents, improved manufacturing of these agents with higher standards is needed. Further, future randomized clinical trials need to evaluate efficacy and safety of these natural agents.
